Vernalis Research develop and apply fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation.
The Company balances an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical companies and academic partners. Its shared-risk approach ensures a high level of engagement from our scientists and rewards success. Current disclosed collaborations include those with Servier, Daiichi Sankyo, Lundbeck and Asahi Kasei Pharma, and they seek additional partnerships.
Vernalis Research also have an extensive portfolio of partnered and unpartnered drug candidates in pre-clinical and clinical development.